Delaware |
001-36537 |
83-0480694 |
||||||||||||
|
(State or other jurisdiction of
incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
||||||||||||
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
||||
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
||||
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
||||
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
||||
| Title of each class | Trading Symbol | Name of each exchange on which registered | ||||||
| Common stock, $0.00001 par value per share | TRUP | The NASDAQ Stock Market LLC | ||||||
| (d) | Exhibits | |||||||
| Exhibit No. | Description | |||||||
| Press release regarding financial results issued by Trupanion, Inc. dated February 15, 2024 | ||||||||
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL) | |||||||
TRUPANION, INC. | |||||
By: |
/s/ Fawwad Qureshi | ||||
Name: Fawwad Qureshi |
|||||
Title: Chief Financial Officer |
|||||


| Trupanion, Inc. Consolidated Statements of Operations (in thousands, except share data) | |||||||||||||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | ||||||||||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||
| (unaudited) | (unaudited) | ||||||||||||||||||||||
| Revenue: | |||||||||||||||||||||||
| Subscription business | $ | 191,537 | $ | 158,562 | $ | 712,906 | $ | 596,610 | |||||||||||||||
| Other business | 104,320 | 87,447 | 395,699 | 308,569 | |||||||||||||||||||
| Total revenue | 295,857 | 246,009 | 1,108,605 | 905,179 | |||||||||||||||||||
| Cost of revenue: | |||||||||||||||||||||||
Subscription business(1) |
158,631 | 131,823 | 613,686 | 497,684 | |||||||||||||||||||
| Other business | 97,162 | 80,537 | 363,903 | 285,310 | |||||||||||||||||||
Total cost of revenue(2) |
255,793 | 212,360 | 977,589 | 782,994 | |||||||||||||||||||
| Operating expenses: | |||||||||||||||||||||||
Technology and development(1) |
5,969 | 6,955 | 21,403 | 25,133 | |||||||||||||||||||
General and administrative(1) |
13,390 | 10,472 | 60,207 | 39,379 | |||||||||||||||||||
New pet acquisition expense(1) |
17,189 | 22,457 | 77,372 | 89,500 | |||||||||||||||||||
| Depreciation and amortization | 3,029 | 2,897 | 12,474 | 10,921 | |||||||||||||||||||
| Total operating expenses | 39,577 | 42,781 | 171,456 | 164,933 | |||||||||||||||||||
| Gain (loss) from investment in joint venture | (79) | (85) | (219) | (253) | |||||||||||||||||||
| Operating loss | 408 | (9,217) | (40,659) | (43,001) | |||||||||||||||||||
| Interest expense | 3,697 | 1,587 | 12,077 | 4,267 | |||||||||||||||||||
| Other income, net | (1,256) | (1,504) | (7,701) | (3,072) | |||||||||||||||||||
| Loss before income taxes | (2,033) | (9,300) | (45,035) | (44,196) | |||||||||||||||||||
| Income tax expense (benefit) | 130 | (15) | (342) | 476 | |||||||||||||||||||
| Net loss | $ | (2,163) | $ | (9,285) | $ | (44,693) | $ | (44,672) | |||||||||||||||
| Net loss per share: | |||||||||||||||||||||||
| Basic and diluted | $ | (0.05) | $ | (0.23) | $ | (1.08) | $ | (1.10) | |||||||||||||||
| Weighted average shares of common stock outstanding: | |||||||||||||||||||||||
| Basic and diluted | 41,716,527 | 40,936,507 | 41,436,882 | 40,765,355 | |||||||||||||||||||
(1)Includes stock-based compensation expense as follows: |
Three Months Ended December 31, | Year Ended December 31, | |||||||||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||
| Cost of revenue | $ | 1,478 | $ | 1,346 | $ | 5,279 | $ | 6,484 | |||||||||||||||
| Technology and development | 861 | 1,549 | 2,846 | 4,742 | |||||||||||||||||||
| General and administrative | 3,269 | 3,550 | 17,717 | 12,831 | |||||||||||||||||||
| New pet acquisition expense | 1,693 | 2,122 | 7,319 | 9,336 | |||||||||||||||||||
| Total stock-based compensation expense | $ | 7,301 | $ | 8,567 | $ | 33,161 | $ | 33,393 | |||||||||||||||
(2)The breakout of cost of revenue between veterinary invoice expense and other cost of revenue is as follows: | |||||||||||||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | ||||||||||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||
| Veterinary invoice expense | $ | 217,739 | $ | 176,083 | $ | 831,055 | $ | 649,737 | |||||||||||||||
| Other cost of revenue | 38,054 | 36,277 | 146,534 | 133,257 | |||||||||||||||||||
| Total cost of revenue | $ | 255,793 | $ | 212,360 | $ | 977,589 | $ | 782,994 | |||||||||||||||
| Trupanion, Inc. Consolidated Balance Sheets (in thousands, except share data) | |||||||||||
| December 31, 2023 | December 31, 2022 | ||||||||||
| (unaudited) | |||||||||||
| Assets | |||||||||||
| Current assets: | |||||||||||
| Cash and cash equivalents | $ | 147,501 | $ | 65,605 | |||||||
| Short-term investments | 129,667 | 156,804 | |||||||||
| Accounts and other receivables, net of allowance for doubtful accounts of $1,085 at December 31, 2023 and $540 at December 31, 2022 | 267,899 | 232,439 | |||||||||
| Prepaid expenses and other assets | 17,022 | 14,248 | |||||||||
| Total current assets | 562,089 | 469,096 | |||||||||
| Restricted cash | 22,963 | 19,032 | |||||||||
| Long-term investments | 12,866 | 7,841 | |||||||||
| Property, equipment and internal-use software, net | 103,650 | 90,701 | |||||||||
| Intangible assets, net | 18,745 | 24,031 | |||||||||
| Other long-term assets | 18,922 | 18,943 | |||||||||
| Goodwill | 43,713 | 41,983 | |||||||||
| Total assets | $ | 782,948 | $ | 671,627 | |||||||
| Liabilities and stockholders’ equity | |||||||||||
| Current liabilities: | |||||||||||
| Accounts payable | $ | 10,505 | $ | 9,471 | |||||||
| Accrued liabilities and other current liabilities | 34,052 | 32,616 | |||||||||
| Reserve for veterinary invoices | 63,238 | 43,734 | |||||||||
| Deferred revenue | 235,329 | 202,692 | |||||||||
| Long-term debt - current portion | 1,350 | 1,103 | |||||||||
| Total current liabilities | 344,474 | 289,616 | |||||||||
| Long-term debt | 127,580 | 68,354 | |||||||||
| Deferred tax liabilities | 2,685 | 3,392 | |||||||||
| Other liabilities | 4,487 | 4,968 | |||||||||
| Total liabilities | 479,226 | 366,330 | |||||||||
| Stockholders’ equity: | |||||||||||
| Common stock: $0.00001 par value per share, 100,000,000 shares authorized; 42,887,052 and 41,858,866 issued and outstanding at December 31, 2023; 42,041,344 and 41,013,158 shares issued and outstanding at December 31, 2022 | — | — | |||||||||
| Preferred stock: $0.00001 par value per share, 10,000,000 shares authorized; no shares issued and outstanding | — | — | |||||||||
| Additional paid-in capital | 536,108 | 499,694 | |||||||||
| Accumulated other comprehensive loss | 403 | (6,301) | |||||||||
| Accumulated deficit | (216,255) | (171,562) | |||||||||
| Treasury stock, at cost: 1,028,186 shares at December 31, 2023 and December 31, 2022 | (16,534) | (16,534) | |||||||||
| Total stockholders’ equity | 303,722 | 305,297 | |||||||||
| Total liabilities and stockholders’ equity | $ | 782,948 | $ | 671,627 | |||||||
| Trupanion, Inc. Consolidated Statements of Cash Flows (in thousands) | |||||||||||||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | ||||||||||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||
| (unaudited) | (unaudited) | ||||||||||||||||||||||
| Operating activities | |||||||||||||||||||||||
| Net loss | $ | (2,163) | $ | (9,285) | $ | (44,693) | $ | (44,672) | |||||||||||||||
| Adjustments to reconcile net loss to cash provided by (used in) operating activities: | |||||||||||||||||||||||
| Depreciation and amortization | 3,029 | 2,897 | 12,474 | 10,921 | |||||||||||||||||||
| Stock-based compensation expense | 7,301 | 8,567 | 33,161 | 33,393 | |||||||||||||||||||
| Other, net | 2,481 | 1,023 | 1,347 | 1,051 | |||||||||||||||||||
| Changes in operating assets and liabilities: | |||||||||||||||||||||||
| Accounts and other receivables | 10,153 | (8,034) | (35,440) | (66,982) | |||||||||||||||||||
| Prepaid expenses and other assets | 854 | (807) | (1,907) | (5,227) | |||||||||||||||||||
| Accounts payable, accrued liabilities, and other liabilities | 5,476 | 2,388 | 1,644 | 3,136 | |||||||||||||||||||
| Reserve for veterinary invoices | 1,788 | 4,164 | 19,485 | 4,227 | |||||||||||||||||||
| Deferred revenue | (11,412) | 106 | 32,567 | 56,153 | |||||||||||||||||||
| Net cash provided by (used in) operating activities | 17,507 | 1,019 | 18,638 | (8,000) | |||||||||||||||||||
| Investing activities | |||||||||||||||||||||||
| Purchases of investment securities | (56,547) | (147,346) | (165,936) | (273,006) | |||||||||||||||||||
| Maturities and sales of investment securities | 42,905 | 134,718 | 190,270 | 239,210 | |||||||||||||||||||
| Cash paid in business acquisition, net of cash acquired | — | (12,279) | — | (15,034) | |||||||||||||||||||
| Purchases of property, equipment, and internal-use software | (3,970) | (5,478) | (18,280) | (17,088) | |||||||||||||||||||
| Other | 165 | (167) | 1,585 | (1,598) | |||||||||||||||||||
| Net cash provided by (used in) investing activities | (17,447) | (30,552) | 7,639 | (67,516) | |||||||||||||||||||
| Financing activities | |||||||||||||||||||||||
| Proceeds from debt financing, net of financing fees | — | 14,826 | 60,102 | 69,138 | |||||||||||||||||||
| Repayment of debt financing | (337) | (271) | (1,717) | (571) | |||||||||||||||||||
| Repurchases of common stock | — | — | — | (5,755) | |||||||||||||||||||
| Proceeds from exercise of stock options | 1,374 | 706 | 2,655 | 2,290 | |||||||||||||||||||
| Shares withheld to satisfy tax withholding | (240) | (579) | (1,536) | (4,359) | |||||||||||||||||||
| Other | (228) | — | (378) | — | |||||||||||||||||||
| Net cash provided by (used in) financing activities | 569 | 14,682 | 59,126 | 60,743 | |||||||||||||||||||
| Effect of foreign exchange rate changes on cash, cash equivalents, and restricted cash, net | 1,254 | 505 | 424 | (1,459) | |||||||||||||||||||
| Net change in cash, cash equivalents, and restricted cash | 1,883 | (14,346) | 85,827 | (16,232) | |||||||||||||||||||
| Cash, cash equivalents, and restricted cash at beginning of period | 168,581 | 98,983 | 84,637 | 100,869 | |||||||||||||||||||
| Cash, cash equivalents, and restricted cash at end of period | $ | 170,464 | $ | 84,637 | $ | 170,464 | $ | 84,637 | |||||||||||||||
| The following tables set forth our key operating metrics: | |||||||||||||||||||||||||||||||||||||||||||||||
| Year Ended December 31, | |||||||||||||||||||||||||||||||||||||||||||||||
| 2023 | 2022 | ||||||||||||||||||||||||||||||||||||||||||||||
| Total Business: | |||||||||||||||||||||||||||||||||||||||||||||||
| Total pets enrolled (at period end) | 1,714,473 | 1,537,573 | |||||||||||||||||||||||||||||||||||||||||||||
| Subscription Business: | |||||||||||||||||||||||||||||||||||||||||||||||
| Total subscription pets enrolled (at period end) | 991,426 | 869,862 | |||||||||||||||||||||||||||||||||||||||||||||
| Monthly average revenue per pet | $ | 65.26 | $ | 63.82 | |||||||||||||||||||||||||||||||||||||||||||
| Lifetime value of a pet, including fixed expenses | $ | 419 | $ | 641 | |||||||||||||||||||||||||||||||||||||||||||
| Average pet acquisition cost (PAC) | $ | 228 | $ | 289 | |||||||||||||||||||||||||||||||||||||||||||
| Average monthly retention | 98.49 | % | 98.69 | % | |||||||||||||||||||||||||||||||||||||||||||
| Three Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||
| Dec. 31, 2023 | Sep. 30, 2023 | Jun. 30, 2023 | Mar. 31, 2023 | Dec. 31, 2022 | Sep. 30, 2022 | Jun. 30, 2022 | Mar. 31, 2022 | ||||||||||||||||||||||||||||||||||||||||
| Total Business: | |||||||||||||||||||||||||||||||||||||||||||||||
| Total pets enrolled (at period end) | 1,714,473 | 1,712,177 | 1,679,659 | 1,616,865 | 1,537,573 | 1,439,605 | 1,348,145 | 1,267,253 | |||||||||||||||||||||||||||||||||||||||
| Subscription Business: | |||||||||||||||||||||||||||||||||||||||||||||||
| Total subscription pets enrolled (at period end) | 991,426 | 969,322 | 943,958 | 906,369 | 869,862 | 808,077 | 770,318 | 736,691 | |||||||||||||||||||||||||||||||||||||||
| Monthly average revenue per pet | $ | 67.07 | $ | 65.82 | $ | 64.41 | $ | 63.58 | $ | 63.11 | $ | 63.80 | $ | 64.26 | $ | 64.21 | |||||||||||||||||||||||||||||||
| Lifetime value of a pet, including fixed expenses | $ | 419 | $ | 428 | $ | 470 | $ | 541 | $ | 641 | $ | 673 | $ | 713 | $ | 730 | |||||||||||||||||||||||||||||||
| Average pet acquisition cost (PAC) | $ | 217 | $ | 212 | $ | 236 | $ | 247 | $ | 283 | $ | 268 | $ | 309 | $ | 301 | |||||||||||||||||||||||||||||||
| Average monthly retention | 98.49 | % | 98.55 | % | 98.61 | % | 98.65 | % | 98.69 | % | 98.71 | % | 98.74 | % | 98.75 | % | |||||||||||||||||||||||||||||||
| The following table reflects the reconciliation of cash provided by operating activities to free cash flow (in thousands): | |||||||||||||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | ||||||||||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||
| Net cash provided by (used in) operating activities | $ | 17,507 | $ | 1,019 | $ | 18,638 | $ | (8,000) | |||||||||||||||
| Purchases of property, equipment, and internal-use software | (3,970) | (5,478) | (18,280) | (17,088) | |||||||||||||||||||
| Free cash flow | $ | 13,537 | $ | (4,459) | $ | 358 | $ | (25,088) | |||||||||||||||
| The following tables reflect the reconciliation between GAAP and non-GAAP measures (in thousands except percentages): | ||||||||||||||||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | |||||||||||||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||||||||||||
| Veterinary invoice expense | $ | 217,739 | $ | 176,083 | $ | 831,055 | $ | 649,737 | ||||||||||||||||||
| Less: | ||||||||||||||||||||||||||
Stock-based compensation expense1 |
(885) | (899) | (3,450) | (4,054) | ||||||||||||||||||||||
| Other business cost of paying veterinary invoices | (77,572) | (59,946) | (287,858) | (212,857) | ||||||||||||||||||||||
| Subscription cost of paying veterinary invoices (non-GAAP) | $ | 139,282 | $ | 115,238 | $ | 539,747 | $ | 432,826 | ||||||||||||||||||
| % of subscription revenue | 72.7 | % | 72.7 | % | 75.7 | % | 72.5 | % | ||||||||||||||||||
| Other cost of revenue | $ | 38,054 | $ | 36,277 | $ | 146,534 | $ | 133,257 | ||||||||||||||||||
| Less: | ||||||||||||||||||||||||||
Stock-based compensation expense1 |
(386) | (414) | (1,544) | (2,232) | ||||||||||||||||||||||
| Other business variable expenses | (19,301) | (20,591) | (75,756) | (72,453) | ||||||||||||||||||||||
| Subscription variable expenses (non-GAAP) | $ | 18,367 | $ | 15,272 | $ | 69,234 | $ | 58,572 | ||||||||||||||||||
| % of subscription revenue | 9.6 | % | 9.6 | % | 9.7 | % | 9.8 | % | ||||||||||||||||||
| Technology and development expense | $ | 5,969 | $ | 6,955 | $ | 21,403 | $ | 25,133 | ||||||||||||||||||
| General and administrative expense | 13,390 | 10,472 | 60,207 | 39,379 | ||||||||||||||||||||||
| Less: | ||||||||||||||||||||||||||
Stock-based compensation expense1 |
(3,797) | (5,019) | (19,869) | (17,135) | ||||||||||||||||||||||
Non-recurring transaction or restructuring expenses2 |
— | (193) | (4,175) | (372) | ||||||||||||||||||||||
Development expenses3 |
(1,683) | (2,084) | (5,100) | (7,789) | ||||||||||||||||||||||
| Fixed expenses (non-GAAP) | $ | 13,879 | $ | 10,131 | $ | 52,466 | $ | 39,216 | ||||||||||||||||||
| % of total revenue | 4.7 | % | 4.1 | % | 4.7 | % | 4.3 | % | ||||||||||||||||||
| New pet acquisition expense | $ | 17,189 | $ | 22,457 | $ | 77,372 | $ | 89,500 | ||||||||||||||||||
| Less: | ||||||||||||||||||||||||||
Stock-based compensation expense1 |
(1,567) | (2,079) | (7,000) | (9,116) | ||||||||||||||||||||||
| Other business pet acquisition expense | (77) | (65) | (200) | (541) | ||||||||||||||||||||||
| Subscription acquisition cost (non-GAAP) | $ | 15,545 | $ | 20,313 | $ | 70,172 | $ | 79,843 | ||||||||||||||||||
| % of subscription revenue | 8.1 | % | 12.8 | % | 9.8 | % | 13.4 | % | ||||||||||||||||||
1Trupanion employees may elect to take restricted stock units in lieu of cash payment for their bonuses. We account for such expense as stock-based compensation according to GAAP, but we do not include it in any non-GAAP adjustments. Stock-based compensation associated with bonuses was approximately $0.7 million and $1.3 million for the three months and year ended December 31, 2023, respectively. | ||||||||||||||||||||||||||
2Consists of business acquisition transaction expenses, severance and legal costs due to certain executives' departures, and a $3.8 million non-recurring settlement of accounts receivable in the first quarter of 2023 related to uncollected premiums in connection with the transition of underwriting a third-party business to other insurers. | ||||||||||||||||||||||||||
3As we enter the next phase of our growth, we expect to invest in initiatives that are pre-revenue, including adding new products and international expansion. These development expenses are costs related to product exploration and development that are pre-revenue and historically have been insignificant. We view these activities as uses of our adjusted operating income separate from pet acquisition spend. | ||||||||||||||||||||||||||
| The following tables reflect the reconciliation of GAAP measures to non-GAAP measures (in thousands, except percentages): | |||||||||||||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | ||||||||||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||
| Operating Income, GAAP Basis | $ | 408 | $ | (9,217) | $ | (40,659) | $ | (43,001) | |||||||||||||||
| Non-GAAP Expense adjustments | |||||||||||||||||||||||
| Acquisition cost | 15,622 | 20,378 | 70,372 | 80,384 | |||||||||||||||||||
Stock-based compensation expense1 |
6,636 | 8,411 | 31,864 | 32,537 | |||||||||||||||||||
Development expenses3 |
1,683 | 2,084 | 5,100 | 7,789 | |||||||||||||||||||
| Depreciation and amortization | 3,029 | 2,897 | 12,474 | 10,921 | |||||||||||||||||||
Non-recurring transaction or restructuring expenses2 |
— | 193 | 4,175 | 372 | |||||||||||||||||||
| Gain (loss) from investment in joint venture | (79) | (85) | (219) | (253) | |||||||||||||||||||
| Total Adjusted Operating income | $ | 27,457 | $ | 24,831 | $ | 83,545 | $ | 89,255 | |||||||||||||||
| Subscription Business: | |||||||||||||||||||||||
| Subscription Operating Income, GAAP Basis | $ | 1,300 | $ | (8,753) | $ | (35,994) | $ | (39,757) | |||||||||||||||
| Non-GAAP Expense adjustments | |||||||||||||||||||||||
| Acquisition cost | 15,545 | 20,313 | 70,172 | 79,843 | |||||||||||||||||||
Stock-based compensation expense1 |
5,006 | 6,628 | 24,488 | 26,673 | |||||||||||||||||||
Development expenses3 |
1,090 | 1,343 | 3,281 | 5,123 | |||||||||||||||||||
| Depreciation and amortization | 1,961 | 1,867 | 8,021 | 7,205 | |||||||||||||||||||
Non-recurring transaction or restructuring expenses2 |
— | 124 | 218 | 241 | |||||||||||||||||||
| Subscription Adjusted Operating income | $ | 24,902 | $ | 21,522 | $ | 70,186 | $ | 79,328 | |||||||||||||||
| Other Business: | |||||||||||||||||||||||
| Other Business Operating Income, GAAP Basis | $ | (813) | $ | (379) | $ | (4,446) | $ | (2,992) | |||||||||||||||
| Non-GAAP Expense adjustments | |||||||||||||||||||||||
| Acquisition cost | 77 | 65 | 200 | 541 | |||||||||||||||||||
Stock-based compensation expense1 |
1,630 | 1,783 | 7,376 | 5,865 | |||||||||||||||||||
Development expenses3 |
593 | 741 | 1,819 | 2,666 | |||||||||||||||||||
| Depreciation and amortization | 1,068 | 1,030 | 4,453 | 3,716 | |||||||||||||||||||
Non-recurring transaction or restructuring expenses2 |
— | 69 | 3,957 | 131 | |||||||||||||||||||
| Other Business Adjusted Operating income | $ | 2,555 | $ | 3,309 | $ | 13,359 | $ | 9,927 | |||||||||||||||
1Trupanion employees may elect to take restricted stock units in lieu of cash payment for their bonuses. We account for such expense as stock-based compensation according to GAAP, but we do not include it in any non-GAAP adjustments. Stock-based compensation associated with bonuses was approximately $0.7 million and $1.3 million for the three months and year ended December 31, 2023, respectively. | |||||||||||||||||||||||
2Consists of business acquisition transaction expenses, severance and legal costs due to certain executives' departures, and a $3.8 million non-recurring settlement of accounts receivable in the first quarter of 2023 related to uncollected premiums in connection with the transition of underwriting a third-party business to other insurers. | |||||||||||||||||||||||
3As we enter the next phase of our growth, we expect to invest in initiatives that are pre-revenue, including adding new products and international expansion. These development expenses are costs related to product exploration and development that are pre-revenue and historically have been insignificant. We view these activities as uses of our adjusted operating income separate from pet acquisition spend. | |||||||||||||||||||||||
| The following tables reflect the reconciliation of GAAP measures to non-GAAP measures (in thousands, except percentages): | |||||||||||||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | ||||||||||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||
| Subscription revenue | $ | 191,537 | $ | 158,562 | $ | 712,906 | $ | 596,610 | |||||||||||||||
| Subscription cost of paying veterinary invoices | 139,281 | 115,238 | 539,746 | 432,826 | |||||||||||||||||||
| Subscription variable expenses | 18,367 | 15,272 | 69,234 | 58,572 | |||||||||||||||||||
| Subscription fixed expenses* | 8,987 | 6,530 | 33,740 | 25,884 | |||||||||||||||||||
| Subscription adjusted operating income | $ | 24,902 | $ | 21,522 | $ | 70,186 | $ | 79,328 | |||||||||||||||
| Other business revenue | $ | 104,320 | $ | 87,447 | $ | 395,699 | $ | 308,569 | |||||||||||||||
| Other business cost of paying veterinary invoices | 77,572 | 59,946 | 287,858 | 212,857 | |||||||||||||||||||
| Other business variable expenses | 19,301 | 20,591 | 75,756 | 72,453 | |||||||||||||||||||
| Other business fixed expenses* | 4,892 | 3,601 | 18,726 | 13,332 | |||||||||||||||||||
| Other business adjusted operating income | $ | 2,555 | $ | 3,309 | $ | 13,359 | $ | 9,927 | |||||||||||||||
| Revenue | $ | 295,857 | $ | 246,009 | $ | 1,108,605 | $ | 905,179 | |||||||||||||||
| Cost of paying veterinary invoices | 216,854 | 175,184 | 827,605 | 645,683 | |||||||||||||||||||
| Variable expenses | 37,668 | 35,863 | 144,990 | 131,025 | |||||||||||||||||||
| Fixed expenses* | 13,879 | 10,131 | 52,466 | 39,216 | |||||||||||||||||||
| Total business adjusted operating income | $ | 27,457 | $ | 24,831 | $ | 83,545 | $ | 89,255 | |||||||||||||||
| As a percentage of revenue: | Three Months Ended December 31, | Year Ended December 31, | |||||||||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||
| Subscription revenue | 100.0 | % | 100.0 | % | 100.0 | % | 100.0 | % | |||||||||||||||
| Subscription cost of paying veterinary invoices | 72.7 | % | 72.7 | % | 75.7 | % | 72.5 | % | |||||||||||||||
| Subscription variable expenses | 9.6 | % | 9.6 | % | 9.7 | % | 9.8 | % | |||||||||||||||
| Subscription fixed expenses* | 4.7 | % | 4.1 | % | 4.7 | % | 4.3 | % | |||||||||||||||
| Subscription adjusted operating income | 13.0 | % | 13.6 | % | 9.8 | % | 13.3 | % | |||||||||||||||
| Other business revenue | 100.0 | % | 100.0 | % | 100.0 | % | 100.0 | % | |||||||||||||||
| Other business cost of paying veterinary invoices | 74.4 | % | 68.6 | % | 72.7 | % | 69.0 | % | |||||||||||||||
| Other business variable expenses | 18.5 | % | 23.5 | % | 19.1 | % | 23.5 | % | |||||||||||||||
| Other business fixed expenses* | 4.7 | % | 4.1 | % | 4.7 | % | 4.3 | % | |||||||||||||||
| Other business adjusted operating income | 2.4 | % | 3.8 | % | 3.4 | % | 3.2 | % | |||||||||||||||
| Revenue | 100.0 | % | 100.0 | % | 100.0 | % | 100.0 | % | |||||||||||||||
| Cost of paying veterinary invoices | 73.3 | % | 71.2 | % | 74.7 | % | 71.3 | % | |||||||||||||||
| Variable expenses | 12.7 | % | 14.6 | % | 13.1 | % | 14.5 | % | |||||||||||||||
| Fixed expenses* | 4.7 | % | 4.1 | % | 4.7 | % | 4.3 | % | |||||||||||||||
| Total adjusted operating income | 9.3 | % | 10.1 | % | 7.5 | % | 9.9 | % | |||||||||||||||
| *Fixed expenses represent shared services that support both our subscription and other business segments and, as such, are generally allocated to each segment pro-rata based on revenues. | |||||||||||||||||||||||
| The following tables reflect the reconciliation of adjusted EBITDA to net loss (in thousands): | |||||||||||||||||||||||||||||||||||||||||||||||
| Year Ended December 31, | |||||||||||||||||||||||||||||||||||||||||||||||
| 2023 | 2022 | ||||||||||||||||||||||||||||||||||||||||||||||
| Net loss | $ | (44,693) | $ | (44,672) | |||||||||||||||||||||||||||||||||||||||||||
| Excluding: | |||||||||||||||||||||||||||||||||||||||||||||||
| Stock-based compensation expense | 31,864 | 32,537 | |||||||||||||||||||||||||||||||||||||||||||||
| Depreciation and amortization expense | 12,474 | 10,921 | |||||||||||||||||||||||||||||||||||||||||||||
| Interest income | (9,011) | (3,026) | |||||||||||||||||||||||||||||||||||||||||||||
| Interest expense | 12,077 | 4,267 | |||||||||||||||||||||||||||||||||||||||||||||
| Other non-operating expenses | — | (1) | |||||||||||||||||||||||||||||||||||||||||||||
| Income tax (benefit) expense | (342) | 476 | |||||||||||||||||||||||||||||||||||||||||||||
| Non-recurring transaction or restructuring expenses | 4,175 | 372 | |||||||||||||||||||||||||||||||||||||||||||||
| (Gain) loss from equity method investment | (110) | (131) | |||||||||||||||||||||||||||||||||||||||||||||
| Adjusted EBITDA | $ | 6,434 | $ | 743 | |||||||||||||||||||||||||||||||||||||||||||
| Three Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||
| Dec. 31, 2023 | Sep. 30, 2023 | Jun. 30, 2023 | Mar. 31, 2023 | Dec. 31, 2022 | Sep. 30, 2022 | Jun. 30, 2022 | Mar. 31, 2022 | ||||||||||||||||||||||||||||||||||||||||
| Net loss | $ | (2,163) | $ | (4,036) | $ | (13,714) | $ | (24,780) | $ | (9,285) | $ | (12,914) | $ | (13,618) | $ | (8,855) | |||||||||||||||||||||||||||||||
| Excluding: | |||||||||||||||||||||||||||||||||||||||||||||||
| Stock-based compensation expense | 6,636 | 6,585 | 6,503 | 12,140 | 8,412 | 8,306 | 8,462 | 7,358 | |||||||||||||||||||||||||||||||||||||||
| Depreciation and amortization expense | 3,029 | 2,990 | 3,253 | 3,202 | 2,897 | 2,600 | 2,707 | 2,717 | |||||||||||||||||||||||||||||||||||||||
| Interest income | (2,842) | (2,389) | (2,051) | (1,729) | (1,614) | (1,018) | (297) | (97) | |||||||||||||||||||||||||||||||||||||||
| Interest expense | 3,697 | 3,053 | 2,940 | 2,387 | 1,587 | 1,408 | 1,193 | 79 | |||||||||||||||||||||||||||||||||||||||
| Other non-operating expenses | — | — | — | — | — | — | (1) | — | |||||||||||||||||||||||||||||||||||||||
| Income tax expense (benefit) | 130 | (43) | (238) | (191) | (15) | 496 | 19 | (24) | |||||||||||||||||||||||||||||||||||||||
| Non-recurring transaction or restructuring expenses | — | 8 | 65 | 4,102 | 193 | 179 | — | — | |||||||||||||||||||||||||||||||||||||||
| (Gain) loss from equity method investment | — | (110) | — | — | — | — | (131) | — | |||||||||||||||||||||||||||||||||||||||
| Adjusted EBITDA | $ | 8,487 | $ | 6,058 | $ | (3,242) | $ | (4,869) | $ | 2,175 | $ | (943) | $ | (1,666) | $ | 1,178 | |||||||||||||||||||||||||||||||